ClinicalTrials.gg

Program

remibrutinib

Also written as “Remibrutinib”, “LOU064” and “LOU064 (blinded)”.

Its studies are mostly in Chronic Urticaria · Hidradenitis Suppurativa · Pruritus · Rosacea · Food Hypersensitivity, led by Novartis.

Furthest: phase 3, since Aug 19, 202134 company-led studies, 21 open or runningNext primary completion: Feb 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis3421 open or runningphase 3since Aug 19, 2021Dec 14, 2015Feb 22, 2027phase 3 · NCT06868212

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Dec 14, 2015.

  1. Dec 17, 2024Phase 3 study in Myasthenia GravisNCT06744920 · 180 enrolled · United States, Argentina, Australia and more
  2. Jan 23, 2025Phase 3 study in Hidradenitis SuppurativaNCT06799000 · 588 enrolled · United States, Argentina, Australia and more
  3. Feb 17, 20252 phase 3 studiesNCT06840392, NCT06846281
  4. Mar 6, 2025Phase 3 study in Chronic UrticariaNCT06868212 · 409 enrolled · United States
  5. Mar 6, 2025Phase 2 study in Chronic UrticariaNCT06865651 · 44 planned · United States, France, Germany and more
  6. Jun 19, 2025Phase 1 study in Renal InsufficiencyNCT07032272 · 16 enrolled · United States
  7. Nov 4, 2025Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07225504 · 1,275 planned · United States, Argentina, Australia and more
  8. Mar 3, 2026Phase 3 study in Indication of the Parent ProtocolNCT07456891 · 650 planned · Bulgaria, Canada, Colombia and more
  9. Jun 18, 2026Phase 3 study in Hidradenitis SuppurativaNCT07665437 · 710 planned · United States, Argentina, Australia and more
  10. Jun 26, 2026Phase 2 study in RosaceaNCT07681271 · 100 planned · United States, Bulgaria, Canada and more
  11. Jul 7, 2026Phase 3 study in Chronic Pruritus of Unknown OriginNCT07700056 · 180 planned · United States, Argentina, Canada and more
  12. Aug 12, 2026Phase 3 study in Food HypersensitivityNCT07768371 · 576 planned · United States
  13. Sep 4, 20262 phase 3 studiesNCT07811869, NCT07816328
  14. Sep 28, 2026Phase 1 study in Hidradenitis SuppurativaNCT07855276 · 30 planned · United States

Ahead

  1. Nov 3, 2026Primary completion: phase 3 study in Chronic UrticariaNCT05677451
  2. Feb 22, 2027Primary completion: phase 3 study in Chronic UrticariaNCT06868212
  3. May 17, 2027Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06799000
  4. Jun 3, 2027Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06840392

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07855276Hidradenitis Suppurativa · United States1RecruitingNov 29, 202730
NCT07816328Chronic Urticaria · Canada, Hong Kong, Japan and more3RecruitingMay 24, 2028382
NCT07811869Chronic Pruritus of Unknown Origin · United States, Canada, China3RecruitingFeb 26, 2029180
NCT07768371Food Hypersensitivity · United States3RecruitingMar 30, 2029576
NCT07700056Chronic Pruritus of Unknown Origin · United States, Argentina, Canada and more3RecruitingDec 19, 2029180
NCT07681271Rosacea · United States, Bulgaria, Canada and more2RecruitingDec 7, 2027100
NCT07665437Hidradenitis Suppurativa · United States, Argentina, Australia and more3RecruitingOct 15, 2031710
NCT07456891Indication of the Parent Protocol · Bulgaria, Canada, Colombia and more3RecruitingJan 30, 2033650
NCT07225504Multiple Sclerosis, Chronic Progressive · United States, Argentina, Australia and more3RecruitingDec 3, 20301,275
NCT07032272Renal Insufficiency · United States1CompletedOct 12, 202516
NCT06868212Chronic Urticaria · United States3Active, not recruitingFeb 22, 2027409
NCT06865651Chronic Urticaria · United States, France, Germany and more2RecruitingAug 23, 202744
NCT06846281Relapsing Multiple Sclerosis · United States, Argentina, Australia and more3RecruitingJul 25, 2029400
NCT06840392Hidradenitis Suppurativa · United States, Argentina, Austria and more3Active, not recruitingJun 3, 2027565
NCT06799000Hidradenitis Suppurativa · United States, Argentina, Australia and more3Active, not recruitingMay 17, 2027588
NCT06744920Myasthenia Gravis · United States, Argentina, Australia and more3Active, not recruitingFeb 25, 2028180
NCT06042478Chronic Urticaria · Argentina, Brazil, Bulgaria and more3Active, not recruitingSep 17, 2025470
NCT05976243Chronic Inducible Urticaria · United States, Argentina, Australia and more3Active, not recruitingMay 11, 2026362
NCT05795153Chronic Urticaria · United States, Argentina, Canada and more3CompletedApr 25, 2024144
NCT05677451Chronic Urticaria · United States, Argentina, Canada and more3Active, not recruitingNov 3, 2026100
NCT05753592Hepatic Impairment · Hungary1CompletedDec 14, 202338
NCT05513001Chronic Urticaria · United States, Argentina, Australia and more3Active, not recruitingAug 26, 2024696
NCT05432388Peanut Hypersensitivity · United States2CompletedMar 11, 202576
NCT05156281Recurrence · United States, Argentina, Brazil and more3Active, not recruitingJul 22, 20261,007
NCT05147220Recurrence · United States, Argentina, Austria and more3Active, not recruitingJul 21, 20261,000
NCT05048342Chronic Urticaria · Japan3CompletedDec 8, 202371
NCT05032157Chronic Urticaria · United States, Austria, Brazil and more3CompletedDec 18, 2023455
NCT05030311Chronic Urticaria · United States, Argentina, Australia and more3CompletedDec 27, 2023470
NCT04109313Chronic Urticaria · United States, Argentina, Belgium and more2CompletedSep 9, 2022229
NCT04035668Sjogren's Syndrome · United States, Australia, Belgium and more2TerminatedNov 23, 202173
NCT03944707Asthma · United States, Argentina, Germany and more2TerminatedApr 27, 202076
NCT03926611Chronic Urticaria · United States, Argentina, Belgium and more2CompletedJan 14, 2021311
NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more2CompletedDec 4, 2024248
NCT03918980Dermatitis, Atopic · Germany, Netherlands1CompletedJan 27, 2020185

How it is read

Names in the registry

  • “Remibrutinib”, 13 entries
  • “LOU064”, 7 entries
  • “LOU064 (blinded)”, 3 entries
  • “Remibrutinib Dose A”, 2 entries
  • “Remibrutinib Dose B”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.